{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:53:23Z","timestamp":1776153203748,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Posttransplant lymphoproliferative disorder (PTLD) is the most common posttransplant malignancy in children. We reviewed data from 3 Canadian pediatric centers to determine patient characteristics, treatment approaches, and outcomes for children with monomorphic PTLD. There were 55 eligible children diagnosed between January 2001 to December 2021. Forty-eight patients (87.2%) had B-cell PTLD: Burkitt lymphoma (n = 25; 45.4%) and diffuse large B-cell lymphoma (n = 23; 41.2%), the remainder had natural killer (NK)\/T-cell lymphoma (n = 5; 9.1%), Hodgkin lymphoma (n = 1;1.8%), or other (n = 1;1.8%). Thirty-nine (82.1%) patients with B-cell PTLD were treated with rituximab and chemotherapy with or without a reduction in immunosuppression (reduced immune suppression). The chemotherapy used was primarily one of 2 regimens: Mature Lymphoma B-96 protocol in 22 patients (56.4%) and low-dose cyclophosphamide with prednisone in 14 patients (35%). Most patients with T\/NK-cell lymphoma were treated with reduced immune suppression + chemotherapy (n = 4; 80%). For all patients with monomorphic PTLD, the projected 3-year event-free survival\/3-year overall survival was 62% and 77%, respectively. Of the patients, 100% with T\/NK-cell PTLD 100% progressed or relapsed and, subsequently, died of disease. For patients with B-cell PTLD, there was no significant difference in outcome between the two main chemotherapy regimens employed.<\/jats:p>","DOI":"10.1097\/mph.0000000000002804","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T09:00:21Z","timestamp":1703494821000},"page":"e127-e130","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Monomorphic Posttransplant Lymphoproliferative Disorder in Pediatric Solid Organ Transplant: A Multicenter Review"],"prefix":"10.1097","volume":"46","author":[{"given":"Catherine","family":"Mark","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Toronto Hospital for Sick Children, Toronto, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Jim Pattison Children\u2019s Hospital, Saskatoon, SK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjorn","family":"Baadjes","sequence":"additional","affiliation":[{"name":"Department of Paediatric Hematology\/Oncology, BC Children\u2019s Hospital, Vancouver, British CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley V.","family":"Geerlinks","sequence":"additional","affiliation":[{"name":"Department of Paediatric Hematology\/Oncology, Children\u2019s Hospital, London Health Sciences Centre, Western University, London, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Punnett","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Toronto Hospital for Sick Children, Toronto, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Lafay-Cousin","sequence":"additional","affiliation":[{"name":"Department of Paediatric Hematology\/Oncology and Bone Marrow Transplant, Alberta Children\u2019s Hospital, Calgary, AB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,12,25]]},"reference":[{"key":"R1-20250804","first-page":"8","article-title":"Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop","volume":"14","author":"Harris","year":"1997","journal-title":"Semin Diagn Pathol"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00292-010-1407-x","article-title":"Transplant-associated lymphoproliferation","volume":"32","author":"Hussein","year":"2011","journal-title":"Pathologe"},{"key":"R4-20250804","first-page":"136","article-title":"Incidence and consequences of post-transplantation lymphoproliferative disorders","volume":"10","author":"Boubenider","year":"1997","journal-title":"J Nephrol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1046\/j.1600-6143.2003.00245.x","article-title":"Tumors and transplantation: the 2003 Third Annual ASTS State-of-the-Art Winter Symposium","volume":"3","author":"Feng","year":"2003","journal-title":"Am J Transplant"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"814973","DOI":"10.1155\/2013\/814973","article-title":"Posttransplant lymphoproliferative disease after pediatric solid organ transplantation","volume":"2013","author":"Mynarek","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/lt.23659","article-title":"Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience","volume":"19","author":"Narkewicz","year":"2013","journal-title":"Liver Transpl"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1034\/j.1399-3046.2001.00059.x","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience","volume":"5","author":"Allen","year":"2001","journal-title":"Pediatr Transplant"},{"key":"R9-20250804","first-page":"e1375","article-title":"Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease\u2014a 20\u2009years experience from Austria","volume":"4","author":"F\u00fcreder","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.pcl.2010.01.011","article-title":"Posttransplant lymphoproliferative diseases","volume":"57","author":"Gross","year":"2010","journal-title":"Pediatr Clin N Am"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1002\/cncr.30923","article-title":"Contribution of solid organ transplant recipients to the pediatric non-Hodgkin lymphoma burden in the United States","volume":"123","author":"Yanik","year":"2017","journal-title":"Cancer"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1111\/j.1600-6143.2012.04206.x","article-title":"Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children\u2019s Oncology Group report","volume":"12","author":"Gross","year":"2012","journal-title":"Am J Transplant"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1200\/JCO.2005.08.074","article-title":"Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation","volume":"23","author":"Gross","year":"2005","journal-title":"J Clin Oncol"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1002\/cncr.26001","article-title":"Post-transplant Burkitt Lymphoma is a more aggressive and distinct form of post-transplant lymphoproliferative disorder","volume":"117","author":"Picarsic","year":"2011","journal-title":"Cancer"},{"key":"R15-20250804","first-page":"661","article-title":"Current practices on diagnosis, prevention, and treatment of post-transplant lymphoproliferative disorder in pediatric patients after solid organ transplantation: results of ERN transplant child healthcare working group survey","volume":"8","author":"Baker","year":"2021","journal-title":"Children (Basel)"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3324\/haematol.11360","article-title":"Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease","volume":"92","author":"Gonz\u00e1lez-Barca","year":"2007","journal-title":"Haematologica"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with stage III\/IV B-cell non-Hodgkin lymphoma: a Children\u2019s Oncology Group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2005-01-0377","article-title":"Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study","volume":"107","author":"Choquet","year":"2006","journal-title":"Blood"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","article-title":"Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial","volume":"35","author":"Trappe","year":"2017","journal-title":"J Clin Oncol"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1182\/blood.V124.21.4468.4468","article-title":"Response-adapted sequential immuno-chemotherapy of post-transplant lymphoproliferative disorders in pediatric solid organ transplant recipients: results from the prospective Ped-PTLD 2005 trial","volume":"124","author":"Maecker-Kolhoff","year":"2014","journal-title":"Blood"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1200\/JCO.2005.01.0934","article-title":"Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders","volume":"23","author":"Ghobrial","year":"2005","journal-title":"J Clin Oncol"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/pbc.23004","article-title":"Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD)","volume":"57","author":"Giraldi","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/TP.0000000000000845","article-title":"Risk-adapted treatment for severe B-lineage posttransplant lymphoproliferative disease after solid organ transplantation in children","volume":"100","author":"Giraldi","year":"2016","journal-title":"Transplantation"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/TP.0b013e318277e344","article-title":"Characteristics of early and late PTLD development in pediatric solid organ transplant recipients","volume":"95","author":"Schober","year":"2013","journal-title":"Transplantation"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2021-147274","article-title":"Multicenter, open-label, phase 3 study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant recipients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE)","volume":"138","author":"Prockop","year":"2021","journal-title":"Blood"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"963689721996649","DOI":"10.1177\/0963689721996649","article-title":"Successful treatment of pediatric refractory Burkitt Lymphoma PTLD after liver transplantation using anti-CD19 chimeric antigen receptor T-cell therapy","volume":"30","author":"Wang","year":"2021","journal-title":"Cell Transplant"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.18498","article-title":"Burkitt lymphoma after solid-organ transplant: treatment and outcomes in the paediatric PTLD collaborative","volume":"200","author":"Afify","year":"2023","journal-title":"Br J Haematol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:04:52Z","timestamp":1754337892000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,25]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002804","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,25]]},"assertion":[{"value":"2023-05-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}